Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus

Transplantation

Volumn 86, Issue 4, 2008, Pages 620-622

  Morales, José M ^a   Grinyó, Josep M ^b   Campistol, Josep M ^c   García Martínez, Javier ^d   Arias, Manuel ^e   Paul, Javier ^f   Sánchez Fructuoso, Ana ^g   Brunet, Mercé ^h   Granados, Enrique ⁱ   Munoz Robles, Jorge A ⁱ  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h Therapeutic Drug Monitoring Unit   (Spain)

ⁱ SA   (Spain)

Author keywords

Kidney transplantation; Proteinuria; Renal function; Sirolimus; Tacrolimus; Withdrawal

Indexed keywords

ANTILIPEMIC AGENT; CREATININE; INSULIN; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; STEROID; TACROLIMUS; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG COMBINATION; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; PILOT STUDY; TIME;

ADRENAL CORTEX HORMONES; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; PILOT PROJECTS; PROTEINURIA; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 52449098695     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181821c25     Document Type: Article

References (16)

1. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303.
2. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immuno-suppression comparing sirolimus vs MMF. Am J Transplant 2006; 6: 1617.
3. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J f Transplant 2006; 6: 531.
4. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
5. van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 1934.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273.
7. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.
8. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308.
9. Kaplan B, Kirk AD. Tacrolimus and sirolimus: When bad things happen to good drugs. Am J Transplant 2006; 6: 1501.
10. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869.
11. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198.
12. Arias M, Fernandez-Fresnedo G, Rodrigo E, et al. Non-immunologic intervention in chronic allograft nephropathy. Kidney Int Suppl 2005; (99): S118.
13. Serón D, Arias M, Campistol JM, et al, The Spanish Chronic Allograft Nephropathy Study Group. Late renal allograft failure between 1990 and 1998 in Spain: A changing scenario. Transplantation 2003; 76: 1588.
14. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
15. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, et al. Proteinuria: A new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004; 19 (Suppl 3): III47.
16. Morales JM, Wrammer L, Kreis H, et al. Sirolimus does not exhibit neprhotoxicity compared to cyclosporine in renal transplant recipient. Am J Transpl 2002; 2: 436.